Abstract

Worldwide, it is estimated that SCCA will develop in > 27,000 patients (pts). Twenty percent of pts will develop metastatic (met) disease for which there is no standard approach in the refractory setting. We have previously demonstrated that > 90% of metastatic SCCA is associated with HPV carcinogenesis. Nivolumab (Nivo), a monoclonal antibody targeting PD-1 on T cells, promotes immune-mediated anti-tumor activity of T cells against HPV-positive cells in vitro. We proceeded to conduct the first phase II trial of Nivo in previously treated met SCCA pts.